Stockreport

FDA lifts partial clinical hold on Vigil Neuroscience's Phase I VG-3927 trial [Yahoo! Finance]

Vigil Neuroscience, Inc.  (VIGL) 
PDF Vigil Neuroscience's Phase I trial of VG-3927, a novel treatment under development for neurodegenerative diseases. This decision follows a complete response submitted [Read more]